Showing 61 - 70 of 29,405
Persistent link: https://www.econbiz.de/10001589534
We provide causal evidence that regulation induced product shocks significantly impact aggregate demand and firm performance in pharmaceutical markets. Event study results suggest an average loss between $569 million and $882 million. Affected products lose, on average, $186 million over their...
Persistent link: https://www.econbiz.de/10012911697
The home-market effect, first hypothesized by Linder (1961) and later formalized by Krugman (1980), is the idea that countries with larger demand for some products at home tend to have larger sales of the same products abroad. In this paper, we develop a simple test of the home-market effect...
Persistent link: https://www.econbiz.de/10012984754
Drug development is costly so drug makers need accurate estimates of sales potential. However, sales forecasts are often unreliable. Our study is unique in combining a large sample of drug classes with data on entry order and promotional spending to estimate peak market share while controlling...
Persistent link: https://www.econbiz.de/10012994767
Despite the importance of patient insurance in the market for prescription pharmaceuticals, little is known about the impact of insurance on the pricing behavior of pharmaceutical firms. This paper examines the link between insurance and pricing using a unique policy experiment from Germany....
Persistent link: https://www.econbiz.de/10013221509
This paper studies how patent rights and price regulation affect how fast new drugs are launched in different countries, using newly constructed data on launches of 642 new drugs in 76 countries for the period 1983-2002, and information on the duration and content of patent and price control...
Persistent link: https://www.econbiz.de/10013032477
We provide causal evidence that regulatory shocks associated with drug safety label changes lead to aggregate demand declines of 16.9 percent within two years of a relabeling event. After accounting for all plausible substitution patterns by physicians along with competitor actions, aggregate...
Persistent link: https://www.econbiz.de/10012480610
Despite the importance of patient insurance in the market for prescription pharmaceuticals, little is known about the impact of insurance on the pricing behavior of pharmaceutical firms. This paper examines the link between insurance and pricing using a unique policy experiment from Germany....
Persistent link: https://www.econbiz.de/10012470878
There is a wide consensus that the chronological order of firms entering new product markets can affect long-term market shares. Commonly, it is expected that early entrants are able to gain long-lasting competitive advantages over their followers. This is corroborated by a large body of...
Persistent link: https://www.econbiz.de/10011627887
Persistent link: https://www.econbiz.de/10012009099